Hims & Hers Health (NYSE:HIMS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02, Zacks reports. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Hims & Hers Health Stock Up 4.2 %

Shares of HIMS traded up $2.09 during mid-day trading on Monday, reaching $51.37. 57,301,294 shares of the company’s stock were exchanged, compared to its average volume of 18,979,422. Hims & Hers Health has a 52-week low of $9.67 and a 52-week high of $72.98. The company has a market cap of $11.22 billion, a price-to-earnings ratio of 116.75 and a beta of 1.35. The company has a 50-day simple moving average of $35.05 and a two-hundred day simple moving average of $25.83.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HIMS. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Needham & Company LLC increased their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Bank of America upped their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.53.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the sale, the insider now directly owns 165,254 shares in the company, valued at approximately $4,941,094.60. The trade was a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,082,618 shares of company stock worth $37,317,410. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.